The Natural History of Chronic HBV Infection and Geographical Differences

@article{Liaw2010TheNH,
  title={The Natural History of Chronic HBV Infection and Geographical Differences},
  author={Y F Liaw and Maurizia Rossana Brunetto and Stephanos J. Hadziyannis},
  journal={Antiviral Therapy},
  year={2010},
  volume={15},
  pages={25 - 33}
}
Although chronic HBV infection is a global health issue, there are geographical differences in the mode of transmission, prevalence and HBV genotype distribution. Chronic HBV infection is a dynamic state of interactions between HBV, hepatocytes and immune cells of the host. Accordingly, the natural history of chronic HBV infection typically starts with an immune tolerant phase, followed by an immune clearance phase and finally an inactive phase. The duration of the immune tolerant phase is… 

Figures and Tables from this paper

[Natural history of chronic hepatitis B virus infection].
TLDR
The natural history of chronic HBV infection is reviewed describing the early replicative phase and late or non-Replicative (inactive carrier) in those patients who adquired the infection during adulthood and the immune tolerant phase, immune clearance and non-replicative in those who acquired the infection in the perinatal period.
Anti‐HBs seroconversion during treatment with entecavir in a patient with chronic hepatitis B virus infection on hemodialysis
TLDR
This is the first report of antiviral therapy with entecavir started during the immune reactive phase of HBV infection in a patient on hemodialysis and it suggests that antiviral treatment can enhance the effects of host immune activation resulting in biochemical, serological, and viral response, even in end‐stage renal failure patients with partial immunodeficiency.
Prevention of hepatitis B virus infection: from the past to the future
About 3–5 % of the world’s population is chronically infected by hepatitis B virus (HBV) and is at risk of developing liver cirrhosis or hepatocellular carcinoma. The risk of dying prematurely
ChronichepatitisB Virus Infection: Diagnosis and Therapy
TLDR
Practice guidelines on the management of hepatitis include achievement of HBeAgseroconversion, and suppression of HBV DNA below the level of detection, and prevent progression to cirrhosis and HCC, and prolong survival.
Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh
The direct cytopathic effects of the hepatitis B virus (HBV) on subsequent liver damage are not fully understood in HBV-infected patients. However, associations between the prevalence of various HBV
Clinical relevance of hepatitis B virus variants.
TLDR
HBV molecular virology, mechanism of variant development, and their potential clinical impact are discussed, including response to antiviral therapy, disease severity and long-term clinical outcomes.
Natural history of chronic hepatitis B: phases in a complex relationship.
TLDR
The understanding of the natural history of CHB has evolved significantly over the past few decades and characterizing the phase of disease remains an integral part of managing this virus in the clinic.
Hepatitis B virus burden in developing countries.
TLDR
The studies on molecular epidemiology performed in some countries provide an important contribution for a more comprehensive knowledge of HBV epidemiology, and phylogenetic studies provide information on the impact of recent and older migratory flows.
Prevalence and endemicity
TLDR
The global epidemiology and the natural history of HBV infection is reviewed, with emphasis on summarizing the different HBV genotypes according to regions, with the aim of explaining geographical differences more pertinently.
Natural history of chronic hepatitis B in Euro-Mediterranean and African countries.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 89 REFERENCES
Natural history of chronic hepatitis B virus infection and long‐term outcome under treatment
  • Y. Liaw
  • Biology, Medicine
    Liver international : official journal of the International Association for the Study of the Liver
  • 2009
TLDR
Among the currently available anti‐HBV drugs, the most extensive and longest experience has been gained with conventional interferon (IFN)‐α and lamivudine and a finite course of IFN therapy has long‐term benefit in achieving a cumulative response, increasing HBsAg seroclearance and reducing cirrhosis and/or HCC.
Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion
TLDR
Patients with persistent HBeAg seropositivity over 40’years of age are associated with a significantly higher risk for progression to cirrhosis than those with HBe Ag seroconversion before 40 years ofAge, and thus should be considered as patients with ‘delayed’ HBeag seroconversions.
Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.
TLDR
The long-term outcome of chronic hepatitis B is different in patients infected with HBV genotype A, D, or F, and sustained remission and clearance of HBsAg were associated with infection with genotypes A by Cox regression analysis.
Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection.
The relationship between the histological diagnosis and serological and tissue markers of HBV replication in 41 Greek and 29 British patients with chronic HBV infection were studied. All the nine
Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma.
TLDR
Although HBV genotype B dominates in children with chronic HBV infection and HCC in Taiwan, genotype C delays HBeAg seroconversion in pediatric chronicHBV infection.
The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B
  • B. McMahon
  • Biology, Medicine
    Hepatology international
  • 2009
TLDR
It is suggested that HBV genotypes/subgenotypes have important influences on the outcome of chronic HBV infection, but more population-based prospective studies examining multiple genotypes are needed.
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
  • D. Lavanchy
  • Medicine, Biology
    Journal of viral hepatitis
  • 2004
TLDR
More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV‐related morbidity and mortality.
Hepatitis B Virus Replication and Liver Disease Progression: The Impact of Antiviral Therapy
  • Y. Liaw
  • Medicine, Biology
    Antiviral therapy
  • 2006
TLDR
In both the woodchuck hepatitis model and in HBV patients, maintained suppression of HBV replication by a direct antiviral agent may reduce the progression to HCC, and the efficacy of current antiviral therapy is still far from satisfactory.
Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment.
TLDR
The long-term resistance profile of adefovir is significantly better than that of lamivudine (LMV), whereas data for entecavir currently are limited to 2 years, with resistance developing in LMV-resistant but not in treatment-naïve patients.
...
1
2
3
4
5
...